Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Proceedings of the American Thoracic Society 6:151 (2009)
© 2009 The American Thoracic Society
doi: 10.1513/pats.200809-103LC
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jett, J. R.
Right arrow Articles by Socinski, M. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jett, J. R.
Right arrow Articles by Socinski, M. A.

Introduction

James R. Jett, M.D.

Mayo Clinic College of Medicine
Rochester, Minnesota

Mark A. Socinski, M.D.

Multidisciplinary Thoracic Oncology Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina

Lung cancer has been and remains the number one cancer killer in North America and the western world. There have been dramatic changes in diagnosis, staging, and treatment options in the past 5 to 10 years, as well as a spectacular expansion in our understanding of the molecular biology of this disease. The purpose of this virtual symposium was to help keep pulmonary medicine specialists and scientists abreast of these rapid changes. Much of this new information is published in journals that are not typically read by the pulmonary community. Our goal was to bring this new knowledge together in one symposium. Included are state of the art articles on bronchoscopic ultrasound (EBUS) and positron emission tomography (PET). Genomic changes related to lung cancer are reviewed along with a comprehensive assessment of nucleotide excision repair genes and their potential importance in selecting the most effective chemotherapeutic agents for treatment. The current status of chemoprevention, role of adjuvant chemotherapy, and treatment of advanced non–small cell lung cancer are summarized. The reader will also find a review of the status of anti-angiogenic agents and vaccines for treatment.

Our hope is that this symposium will serve as a quick reference regarding the rapid changes that are occurring in this disease and will help expand the reader's understanding of the current state of the art. Given that "knowledge is power," it is anticipated that this information will allow you to deliver the highest level of care available to your patients with this devastating disease.

FOOTNOTES

Conflict of Interest Statement: J.R.J. served on Advisory Boards in 2007 for Genentech, and Amgen. M.A.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.





This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jett, J. R.
Right arrow Articles by Socinski, M. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jett, J. R.
Right arrow Articles by Socinski, M. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS